Amgen presents new Repatha data at ADA meeting

US biotech major Amgen(Nasdaq: AMGN) has announced new data that show Repatha(evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy.

BANTING was a dedicated study evaluating the efficacy of Repatha (monthly dosing), in lowering LDL-C and improving other lipid levels in patients with type 2 diabetes. In addition to meeting criteria for hypercholesterolemia or mixed dyslipidemia, patients in the trial had varying degrees of glycemic control. Data were presented at the American Diabetes Association (ADA) 78th Annual Scientific Sessions.

"Diabetes affects more than 20 million Americans and managing their uncontrolled cholesterol levels remains a critical unmet need," said Sean Harper, executive vice president of R&D at Amgen, adding: "The findings of the BANTING study clearly demonstrate the ability for Repatha to help these patients reach their targets."